德国生物技术公司CureVac当地时间8月8日宣布CureVac和葛兰素史克公司已与BioNTech和辉瑞达成协议解决并

智通财经
Aug 08
德国生物技术公司CureVac当地时间8月8日宣布CureVac和葛兰素史克公司已与BioNTech和辉瑞达成协议解决并驳回几家公司在美国就基于mRNA的新冠疫苗提起的所有未决专利诉讼并为解决美国以外地区正在进行的专利纠纷制定了框架。根据协议条款CureVac和葛兰素史克将获得总计7.4亿美元的付款以及新冠疫苗未来在美国销售的个位数版税。此外CureVac还将从葛兰素史克处收到5000万美元美国产品特许权使用费。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10